Premium
Naturally occurring serum antiidiotypic antibody against antiliver‐specific membrane lipoprotein in patients with hepatitis
Author(s) -
Tsubouchi Akinori,
Yoshioka Kentaro,
Kakumu Shinichi
Publication year - 1985
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840050508
Subject(s) - radioimmunoassay , antibody , lipoprotein , monoclonal antibody , antigen , hepatitis , immunology , microbiology and biotechnology , medicine , cholesterol , biology
Studies were undertaken to evaluate whether antiidiotypic antibody against antiliver‐specific membrane lipoprotein is related to the disease activity of patients with hepatitis. Sera from normal individuals, patients with viral hepatitis and medical staffs were depleted of antiliver‐specific membrane lipoprotein antibody by absorbing with liver‐specific membrane lipoprotein‐bearing cell line SK‐Hep‐1. Anti‐antiliver‐specific membrane lipoprotein was detected by binding activity to antihuman liver‐specific membrane lipoprotein monoclonal antibody using solid‐phase radioimmunoassay and by inhibitory activity for binding of antiliver‐specific membrane lipoprotein monoclonal antibody to SK‐Hep‐1 using competitive radioimmunoassay. The results obtained by the two assays were equivalent for detecting anti‐antiliver‐specific membrane lipoprotein. Sera from patients with acute viral hepatitis during recovery phase (n = 6) and chronic persistent hepatitis (n = 12), respectively, showed significantly increased anti‐antiliver‐specific membrane lipoprotein activity (p < 0.01) when compared to those from normal individuals (n = 10), whereas sera from patients with chronic active liver disease (n = 12) did not reveal significantly different values from controls. Sera from the medical staff (n = 11) who had contact with hepatitis patients also demonstrated increased anti‐antiliver‐specific membrane lipoprotein activity (p < 0.05). Inhibitory activity of anti‐antiliver‐specific membrane lipoprotein in the serum appeared localized within the F(ab‐) 2 fragments of immunoglobulin G fraction by competitive radioimmunoassay. The specificity of the inhibitory activity of the serum was confirmed by its inability to block unrelated antigen‐antibody reactions. These findings suggest that the presence of antibody against antiliver‐specific membrane lipoproteins is related to the disease activity in certain patients with hepatitis.